Evidence map›Paper›PMID 39117755›Full record

ArticleCellular and molecular life sciences : CMLS2024

The AP-1 adaptor complex is essential for intracellular trafficking of the ORF2 capsid protein and assembly of Hepatitis E virus.

Martin Ferrié, Virginie Alexandre, Claire Montpellier, Peggy Bouquet, Thibault Tubiana, Léa Mézière, Maliki Ankavay, Cyrine Bentaleb, Jean Dubuisson, Stéphane Bressanelli and 3 more

Abstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Virus infection and vesicle trafficking.Frontiers in immunology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Martin FerriéUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL- Center for Infection and Immunity of Lille, Lille, F-59000, France.
Virginie AlexandreUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL- Center for Infection and Immunity of Lille, Lille, F-59000, France.
Claire MontpellierUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL- Center for Infection and Immunity of Lille, Lille, F-59000, France.
Peggy BouquetUnit of Clinical Microbiology, Institut Pasteur de Lille, Lille, F-59000, France.
Thibault TubianaInstitute for Integrative Biology of the Cell (I2BC), Université Paris-Saclay, CEA, CNRS, Gif-sur-Yvette, France.
Léa MézièreUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL- Center for Infection and Immunity of Lille, Lille, F-59000, France.
Maliki AnkavayUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL- Center for Infection and Immunity of Lille, Lille, F-59000, France.
Cyrine BentalebUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL- Center for Infection and Immunity of Lille, Lille, F-59000, France.
Jean DubuissonUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL- Center for Infection and Immunity of Lille, Lille, F-59000, France.
Stéphane BressanelliInstitute for Integrative Biology of the Cell (I2BC), Université Paris-Saclay, CEA, CNRS, Gif-sur-Yvette, France.
Cécile-Marie Aliouat-DenisUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL- Center for Infection and Immunity of Lille, Lille, F-59000, France.
Yves RouilléUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL- Center for Infection and Immunity of Lille, Lille, F-59000, France.
Laurence CocquerelUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL- Center for Infection and Immunity of Lille, Lille, F-59000, France. laurence.cocquerel@ibl.cnrs.fr.ORCID http://orcid.org/0000-0002-2136-5178

Funding

Agence Nationale de Recherches sur le Sida et les Hépatites Virales AAP 2015-2Agence Nationale de Recherches sur le Sida et les Hépatites Virales AAP 2015-2, ECTZ61515Agence Nationale de Recherches sur le Sida et les Hépatites Virales ECTZ189696Agence Nationale de Recherches sur le Sida et les Hépatites Virales ECTZ205629Agence Nationale de Recherches sur le Sida et les Hépatites Virales ECTZ74553Inserm-Transfert HEV-CureInstitut Pasteur de Lille HEV-CureInstitut Pasteur de Lille Institut Pasteur de LilleRégion Hauts-de-France HEV-CureRégion Hauts-de-France Région Hauts-de-FranceUniversité de Lille Université de Lille
6 · The paper itself

Abstract

Although the Hepatitis E virus (HEV) is an emerging global health burden, little is known about its interaction with the host cell. HEV genome encodes three proteins including the ORF2 capsid protein that is produced in different forms, the ORF2i protein which is the structural component of viral particles, and the ORF2g/c proteins which are massively secreted but are not associated with infectious material. We recently demonstrated that the endocytic recycling compartment (ERC) is hijacked by HEV to serve as a viral factory. However, host determinants involved in the subcellular shuttling of viral proteins to viral factories are unknown. Here, we demonstrate that the AP-1 adaptor complex plays a pivotal role in the targeting of ORF2i protein to viral factories. This complex belongs to the family of adaptor proteins that are involved in vesicular transport between the trans-Golgi network and early/recycling endosomes. An interplay between the AP-1 complex and viral protein(s) has been described for several viral lifecycles. In the present study, we demonstrated that the ORF2i protein colocalizes and interacts with the AP-1 adaptor complex in HEV-producing or infected cells. We showed that silencing or drug-inhibition of the AP-1 complex prevents ORF2i protein localization in viral factories and reduces viral production in hepatocytes. Modeling of the ORF2i/AP-1 complex also revealed that the S domain of ORF2i likely interacts with the σ1 subunit of AP-1 complex. Hence, our study identified for the first time a host factor involved in addressing HEV proteins (i.e. ORF2i protein) to viral factories.

Indexed as

Adaptor Protein Complex 1Capsid ProteinsHepatitis E virusHepatitis EHumansProtein TransportViral ProteinsVirus AssemblyAdaptor Protein Complex 1Capsid ProteinsORF2 protein, Hepatitis E virusViral ProteinsA5 membrane traffic inhibitorAlphaFold2P1H1 antibodyP3H2 antibodyPLC3 cellsPrimary human hepatocytesProximity ligation assayReplication

Identifiers

PMID39117755
PMCPMC11335258

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.